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ABSTRAK
Morfea merupakan penyakit jaringan penyambung yang jarang dengan gambaran utama berupa penebalan 
dermis tanpa disertai keterlibatan organ dalam. Penyakit ini juga dikenal sebagai bagian dari skleroderma 
terlokalisir. Berdasarkan gambaran klinis dan kedalaman jaringan yang terlibat, morfea dikelompokkan ke dalam 
beberapa bentuk dan sekitar dua pertiga orang dewasa dengan morfea mempunyai tipe plak. Produksi kolagen 
yang berlebihan oleh fibroblast merupakan penyebab kelainan pada morfea dan mekanisme terjadinya aktivitas 
fibroblast yang berlebihan ini masih belum diketahui, meskipun beberapa mekanisme pernah diajukan. Morfe 
tipe plak biasanya bersifat ringan dan dapat sembuh dengan sendirinya. Morfea tipe plak yang penampilan 
klinisnya menyerupai lupus eritematosus sistemik, misalnya meliputi alopesia dan ulkus mukosa di mulut, 
jarang dijumpai.
Sebuah kasus morfea tipe plak pada wanita berusia 20 tahun dibahas. Pasien ini diobati dengan 
imunosupresan dan antioksidan local maupun sistemik. Kondisi paisen membaik tanpa disertai efek samping 
yang berarti.
Kata kunci:  morfea, tipe plak.
ABSTRACT
Morphea is an uncommon connective tissue disease with the most prominent feature being thickening or 
fibrosis of the dermal without internal organ involvement. It is also known as a part of localized scleroderma. 
Based on clinical presentation and depth of tissue involvement, morphea is classified into several forms, and 
about two thirds of adults with morphea have plaque type. Overproduction of collagen production by fibroblast 
is the cause of abnormality in morphea, and the hyperactivity mechanism of fibroblast is still unknown, although 
there are several mechanisms already proposed. Plaque type morphea is actually a benign and self limited. 
Plaque type morphea that mimicking systemic lupus erythematosus in clinical appearance, such as alopecia 
and oral mucosal ulcers, is uncommon.
A case of plaque type morphea mimicking systemic lupus erythematosus in a 20 year old woman was 
discussed. The patient was treated with local and systemic immunosuppressant and antioxydant. The patient’s 
condition is improved without any significant side effects.
Key words: morphea, plaque type.
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INTRODUCTION
Morphea is an uncommon persistent 
condition in which there are areas of thickened 
skin and cutaneus tissue from excessive collagen 
deposition and one of its type is plaque type. It 
is also known as localized scleroderma, and it 
may affect adults and children. Morphea includes 
specific condition raging from very small plaques 
only involving the skin to widespread disease, 
and it is discriminated from systemic sclerosis 
by its supposed no internal organ involvement.1,2
Plaque type morphea is mainly involved 
women. Adequate studies on the incidence and 
prevalence have not been performed. Plaque 
type morphea also may be under-reported as a 
physician may be unaware of this disorder and 
small morphea plaques may be less often referred 
to a Dermatologist or Rheumatologist.2,3
Overproduction of collagen by fibroblast 
in affected tissues is common in plaque type 
morphea, although the mechanism by which 
these fibroblasts are activated is unknown. 
Possible causes of morphea are radiation, 
infection and vaccination, trauma, genetic 
factor, endothelial cell injury, immunologic 
(autoimmunity) and inflammatory activation, 
and dysregulation of collagen production. In 
histologic finding, there is a thickening process 
and homogenous collagen bundles of the skin, 
and since the autoimmunity is the most possible 
cause of plaque type morphea, there are many 
autoantibodies may be found in individual 
affected.1,2 Plaque type morphea is usually a 
benign and self-limiting disease.1
Reported below is a case of a 20-year old 
woman with plaque type morphea, presenting 
with difficulty in swallowing, ulcers on oral 
mucosal and tongue, face redness, loss of hair, 
localized upper and lower arms skin tightness and 
redness, and also pain on chest, and abdomen.
CASE ILLUSTRATION
A 20-year old woman from Ternate, North 
Mollucas, came to our clinic with chief complaint 
of difficulty of swallowing since 1 month ago, 
accompanied by painless oral mucosal ulcers. 
She had a routine evaluation by an internist 
at Ternate and regularly took Celecoxib, 
Esomeprazol, and Chloroquin since the doctor 
said that she had lupus. Before she felt this 
complaint, she already lost her hair slowly since 
2 months ago, face redness about 1 month ago, 
and fever because of the influenza about 2 weeks 
ago followed by the appearance of redness and 
localized, painful, and hard circular plaques on 
the skin, each on her right upper and lower arms.
Since 9 years ago, the patient had 3 episodes 
of pain on her joints especially on both of her 
Figure 1. The patient’s alopecia
Figure 2. Multiple small ulcers at the patient’s oral to 
laryngeal mucosa and tongue
A. Upper arm B. Lower arm
Figure 3. The patient’s right arm (the black arrows show 
lessions).
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feet. The pain came after she got fever, usually 
because of the influenza. The pain and the 
fever disappeared although she did not take any 
medication at all.
In the clinic, the patient was fully conscious, 
blood pressure 120/80 mmHg, pulse rate 87 x/
minute regularly, respiratory rate 20 x/minute, 
regular and symmetrically, the body temperature 
36.6°C, and the body weight 40 kg. There were 
redness on the patient’s face, scarring alopecia 
and the hair easily felt down, pale conjunctiva, 
loss of eyebrows and eyelashes, multiple painless 
small ulcers at the oral to laryngeal mucosa, and 
coated tongue. There was no abnormality on the 
chest examination. The physical examination of 
the abdomen revealed pain on the right upper 
quadrant and there was a flat, soft, and painful 
hepatomegaly, approximately 3 cm below arcus 
costae. We found the extremities were warm on 
palpation and no edema. There were localized, 
hairless, painfull, and hard circular plaques with 
ivory color and violaceous border, about 3 cm in 
diameter, each on the upper and lower right arms. 
The early laboratory examination already 
done a month before in Ternate and 5 days 
before in Manado, demonstrated her hemoglobin 
9.9 g/dL, haematocrite 29.7%, WBC 9,900/µL, 
platelet count 238,000/µL, MCV 52 fL, MCH 
17.3 pg, MCHC 33.3%, ESR 50 mm/hr, fasting 
blood sugar 70 mg%, AST 103 U/L, ALT 140 
U/L, Alkaline Phosphatase 79 U/L, γGT 76 
U/L, blood ureum 20 mg%, serum creatinine 
0.7 mg%, Widal test positive (titer anti O 1/80 
and anti H 1/160), urinalysis was with in normal 
limits, Anti-Nuclear Antibody (ANA) negative, 
LE test negative, and no LE cell was found. 
Electrocardiogram (ECG) dan chest X-ray were 
normal.
Based on all clinical data above, the 
patient was suspected to have systemic lupus 
erythematosus, with the differential diagnosis of 
dermatomyositis and plaque type morphea, and 
she had also anemia because of chronic disease, 
and reactive hepatitis because of typhoid fever 
and drug induced possibly because of chloroquin 
side effect. The patient was treated with cefixime 
100 mg twice daily for the typhoid fever, topical 
tacrolimus for the scalp and mometasone furoate 
for the other parts of body, methylprednisolone 
tablet 4 mg one tablet three times daily for 5 
days continued with twice daily for 10 days, 
astaxanthine capsules 4 mg twice daily, and 
hepatoprotector. The C-Reactive Protein (CRP), 
anti HBs, total HBc, total anti HCV, total IgE, 
ASMA (SMA), C3 and C4 complements, anti-ds-
DNA examinations, abdominal ultrasonography 
examination and consultation to Dermatology 
Department were planned.
On the 15th day of the treatment, the patient 
returned to the clinic. She was in better condition, 
the difficulty of swallowing was reduced, redness 
on the face was starting to resolve, the ulcers at 
oral to laryngeal mucosa were reduced in number 
and size, the hair was no longer easily felt down. 
There were changes on circular skin plaques on 
her upper and lower arms, the pain was reduced, 
the color was turning into normal, the skin was 
more firm than before, and there was a skin 
biopsy lesion. The blood examination results 
were ASMA (SMA) negative, C3 complement 
108 mg/dL (N : 90-180 mg/dL), C4 complement 
26 mg/dL (N : 10-40 mg/dL), anti-ds-DNA 52.1 
IU/mL (N: ≤ 200 IU/mL), CRP 0.39 mg/dL, anti 
HBs < 2 IU/L (non-reactive <10), total anti HBc 
2.58 (non-reactive), total anti HCV negative, 
and total IgE 43.93 IU/mL (N: 0-100 IU/mL). 
Abdominal ultrasonography showed non-
specific hepatomegaly. The consultation with 
Dermatology Department came with skin biopsy 
result at the circular plaque: atropic epidermal, 
lots of dermal collagen bundles, trapped eccrin 
glands between collagen bundles, and bundels 
found also at the fat tissue. The histologic 
findings were likely a morphea at late stage, 
Figure 4. The patient’s chest X-ray
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that  support the plaque type morphea in the late 
sclerotic stage as the diagnosis. The treatment of 
this patient was continued with mycophenolate 
mofetil 180 mg twice daily, astaxanthine capsules 
twice daily, and hepatoprotector.
DISCUSSION
Morphea,  also known as local ized 
scleroderma, is a disorder characterized by 
excessive collagen deposition leading to 
thickening of the dermis, subcutaneus tissues, 
or both. Morphea typically presents between 
age 20 and 40 and affect women 3 times more 
than men.2 According to clinical presentation, 
morphea is devided into 3 types: plaque morphea, 
linear scleroderma, and generalized morphea.4 
The most frequent type of morphea is the plaque 
type (78.8%). The estimated incidence rate of 
morphea is 27 new cases per million population 
per year.2 In this case, the patient is a 20 year old 
woman and from clinical presentation she had 
plaque morphea type.
Many mechanisms are proposed to explain the 
induction of morphea. Autoimmune mechanisms 
are considered to play an important role, and 
infection is considered to be the trigger factor 
Figure 5. Ultrasonography of the patient’s abdomen
Figure 6. The histologic findings of the skin biopsy at the lession
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of morphea.1 The immune system responses to 
autoantigens are induced by cryptic self-epitops 
that are generated by modification of the self-
antigens during apoptosis.5
The clinical presentation of patients with 
plaque type morphea varies depending on the 
level of tissue involvement and extend of the 
lesion. In general, we may find scalp alopecia, 
loss of eyebrows and eyelashes, nail dystrophy, 
restricted respiration if there is extensive truncal 
morphea, restricted mobility, contractures, 
and deformity, muscle weakness if there is 
peripheral nerves involvement, ptosis, extra-
ocular muscle dysfunction, anterior uveitis, 
episcleritis, glaucoma, xerophthalmia, keratitis, 
altered dentition, malocclusion, and asymmetry 
of the tongue.1 The Plaque type of morphea is 
the most common and the lessions are relatively 
superficial, primarily involving the dermis.1 
Plaque-type morphea lesions are characterized 
as circular, indurated palques that range from 1 
cm to more than 20 cm in diameter. They often 
begins as erythematous to violaceous patches 
or slightly edematous  plaques. With the disease 
progression, sclerosis develops centrally as 
the lesions undergo peripheral expansion. The 
surface become smooth and shiny over time, 
with loss of hair follicles and sweat glands. 
The margins are often surrounded by a zone 
of violaceous color or telengiectasias. Over a 
period of months to years, the skin softens and 
the dermis becomes atrophic.1,2,6 In this patient, 
we found the patient had scalp alopecia, loss 
of eyebrows and eyelashes, and 2 plaque type 
morphea lesions, about 3 cm in diameter, each 
on the upper and lower right arms.
On the additional examination in the 
patients with plaque type morphea, there are 
several blood parameters and also the histology 
examination of skin biopsy and other additional 
examinations. To make sure that there is no 
internal organs involvement, beside the routine 
blood parameters, the liver and kiney function 
should be measured and the ECG and chest 
X-ray should be done.1,2 Several studies have 
shown increased levels of anti nuclear antibody, 
rheumatoid factor, anti-single-stranded DNA 
antibodies, anticentromer antibody, antibodies 
to Th/To ribonucleoprotein, antihistone antibody, 
anti-topoisomerase II antibody, Circulating 
Intercellular Adhesion Mollecule-1 (ICAM-1), 
Soluble Vascular Cell Adhesion Mollecule-1 
(sVCAM-1), E-selectin, soluble CD4, CD8, 
CD23, and fibrogenic T-helper 2 cytokines such 
as interleukin (IL)-4, IL-6, and Transforming 
Growth Factor-Beta (TGF-β) in the patients with 
plaque type morphea, and anti-Cu/Zn-superoxide 
dismutase antibodies.7-13 These cytokines recruit 
eosinophils and other inflammatory cells, induce 
fibroblast to synthesize excessive collagen 
and connective-tissue growth factor which 
enchances and perpetuates the fibrotic effect of 
TGF-β.14 Among those serum autoantibodies, 
antitopoisomerase 2-alpha is one of the major 
autoantibodies in localized scleroderma.4
Histologic findings of the skin biopsy from 
the patients with plaque type morphea in the early 
inflammatory stage, the epidermis is flattened 
and athrophic with loss of the rete ridges. There 
is dermal edema and the collagen fibrils become 
eosinophylic. There is a perivascular infiltrate 
of lymphocytes, plasma cells or macrophages.1 
In the late sclerotic stage, the inflammatory 
infiltrate typically disappears. Collagen bundles 
in the reticular dermis and subcutis become 
thick, closely packed, and deeply eosinophylic. 
Atrophic eccrine glands appear to be trapped 
within the middle of the thickened dermis as 
subcutaneus fat is replaced by collagen. A 
paucity of blood vessels is seen and the dermal 
appendages are lost.1,2,6
The patient in this case gave a clinical 
presentation mimicking systemic lupus 
erythematosus but did not give any positive results 
in autoantibody measurements. The histologic 
findings supported the diagnosis as late sclerotic 
stage of plaque type morphea. The possibility 
of the autoantibody measurements did not give 
any positive results was the morphea was in the 
late sclerotic stage. We did not measure all the 
autoantibodies mentioned above because not all 
of them were available. Anemia was possibly 
caused from chronic disease, and the increase 
of liver function was possibly from reactive 
hepatitis because of typhoid fever and the side 
effects of chloroquine. Chloroquine can form 
higly reactive radicals, the hydroperoxides, which 
can cause hepatotoxicity.15 Reactive hepatitis 
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because of typhoid fever may happen in people 
with malnutrition and weakness of the immune 
system.16
The treament of morphea is difficult and 
only a few controlled clinical trials have 
been published. There are 2 kinds of therapy, 
the topical and systemic therapies.16 The 
topical therapies are the ultra-potent topical 
steroids cream in superficial active lessions to 
reduce inflammation, tacrolimus to inhibit T 
cells activation, vitamin D derivatives inhibit 
proliferation of fibroblast lead to softening and 
repigmentation of morphea lession, phototherapy 
using PUVA and UVA-1 will induce matrix 
metallo proteinase that reduces the procollagen 
in the skin.17-19 The systemic therapies are 
immunosuppression using the combination of 
methotrexate and corticosteroids, penicillin 
and penicillamine, oral vitamin D derivatives, 
mycophenolate mofetil which inhibits inosine 
mohophosphate dehydrogenase, an enzyme 
for controlling the novo purine synthesis used 
by proliferating lymphocytes, and vitamin A 
derivatives which inhibits TGF-β.20-22 This patient 
got cefixime 100 mg twice daily for the typhoid 
fever, mometasone furoate, methylprednisolone 
tablet 4 mg one tablet three times daily for 5 
days continued with twice daily for 10 days 
then changed with mycofenolate mofetil 180 mg 
twice daily for the next 15 days, astaxanthine 
capsules 4 mg twice daily as antioxydant, and 
hepatoprotector.
The prognosis of the plaque type morphea 
improved spontaneously within 3-5 years 
although it may last as long as 25 years, but 
atropy, induration and pigment changes may 
persist.6,23 The patient in this case had a good 
prognosis because of the significant clinical 
improvements to the therapies given.
CONCLUSION
A case of plaque type morphea in a 20 year- 
old woman has been discussed. The patient was 
diagnosed with plaque type morphea, anemia 
because of chronic disease, and reactive hepatitis 
hepatitis because of typhoid fever and drug 
induced possibly because of chloroquin side 
effect. The management of this patient were 
cefixime 100 mg twice daily for her typhoid 
fever, topical tacrolimus for the scalp and 
mometasone furoate for other parts of the body, 
methylprednisolone tablet 4 mg one tablet three 
times daily for 5 days continued with twice daily 
for 10 days then changed with mycophenolate 
mofetil 180 mg twice daily, astaxanthine 
capsules  mg twice daily as antioxydant, and 
hepatoprotector. Significant improvements were 
observed. The prognosis of this patient is good.
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